PMC6620858_01
Mediolateral oblique view of the right breast shows a rim of density surrounding the silicone implant (white arrow).
CRIRA2019-6137198.001.jpg
PMC6620858_01_CRIRA2019-6137198.001.jpg
fig1
On the mammography, the mediolateral oblique (MLO) view without compression demonstrates that the right prosthesis is deformed on its anterior surface (Figure 1).
Case 1, representative section of the cell block preparation from effusion fluid. (a) A cluster of lymphoma cells is observed (hematoxylin and eosin); (b) CD30 expression by the neoplastic cells of BIA-ALCL (original magnification 200x).
CRIRA2019-6137198.002.jpg
PMC6620858_01_CRIRA2019-6137198.002.jpg
fig2
The pathologic evaluation of the second part of this sample firstly reveals the presence of atypical cells (Figure 2(a)). Immunohistochemical analysis then demonstrated a moderate and diffused expression of CD30 (Figure 2(b)).
PMC6620858_02
Mediolateral oblique view of the left breast shows a rim of density surrounding the silicone implant (white arrow).
CRIRA2019-6137198.003.jpg
PMC6620858_02_CRIRA2019-6137198.003.jpg
fig3
On the mammography, the mediolateral oblique (MLO) view without compression demonstrates that the left prosthesis is deformed on its anterior pole and a periprosthetic collection developed mainly on the anterior surface of the prosthesis (Figure 3).
Ultrasound of the left breast demonstrates periprosthetic fluid reaction in the inner region (white arrow).
CRIRA2019-6137198.004.jpg
PMC6620858_02_CRIRA2019-6137198.004.jpg
fig4
But it confirmed the existence of a significant left periprosthetic fluid reaction predominant in the inner region (Figure 4).
Case 2, (a) H&E section of the cell block preparation from effusion fluid showing atypical lymphocytes; (b) CD30 immunohistochemistry highlights tumor cells positive for CD30 (original magnification 200x).
CRIRA2019-6137198.005.jpg
PMC6620858_02_CRIRA2019-6137198.005.jpg
fig5
The pathologic evaluation of the second part of this sample identified atypical cells (Figure 5(a)) and a positivity for CD30 (Figure 5(b)).